Matteo Doglio, MD, IRCCS Ospedale San Raffaele, Milan, Italy, discusses the use of CAR T-cell therapy, in particular CAR-Tregs, for autoimmune diseases. Current treatments involve non-specific inflammatory suppression, which is associated with a higher number of side effects and risk of infections. CAR T-cell therapy opens the possibility to generate a more specific treatment. Current studies are investigating the use of CAR-Tregs in systemic lupus erythematous, but its use in other autoimmune diseases will be explored in the future. This interview took place during the 3rd European CAR T-cell Meeting.